Compare Canadian National Railway Co. (CNI) vs Eli Lilly And Co (LLY) Price & Performance

Canadian National Railway (CNI) trades at $125.31, up 0.73% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with 27.23% net income margin and 21.85% ROE, though valuation multiples appear elevated with P/E of 23.44. Recent record grain and propane shipments highlight operational strength, while Q2 2026 earnings due July 24 will be critical for near-term direction.

CNI presents a mixed outlook with strong operational execution offset by premium valuation. The 35% upside to consensus target of $143.25 offers potential, but debt-to-asset ratio rising to 36.61% and competitive pressures warrant caution. Dividend sustainability appears solid with recent $0.92 payout, making it attractive for income investors seeking railroad exposure.

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.